Seminars in Thoracic and Cardiovascular Surgery
Volume 21, Issue 2 , Pages 97-104 , Summer 2009

Current Status of Screening for Malignant Pleural Mesothelioma

  • Harvey I. Pass, MD

      Affiliations

    • Division of Thoracic Surgery and Thoracic Oncology, Department of Cardiothoracic Surgery, NYU Langone Medical Center, New York, New York
    • Corresponding Author InformationAddress reprint requests to Harvey I. Pass, MD, Division of Thoracic Surgery and Thoracic Oncology, Department of Cardiothoracic Surgery, NYU Langone Medical Center, 530 First Avenue, Suite 9V, New York, NY 10016
    • ,
  • Michele Carbone, MD, PhD

      Affiliations

    • Department of Pathology, John A. Burns School of Medicine, University of Hawaii, Honolulu, Hawaii

References 

  1. Carroll S, Hensler D, Abrahamse A, et al. Asbestos litigation costs and compensation: An interim report. Rank Organisation publications; 2002;Report No.: ISBN:0-8330-3294. DB-397-ICJ
  2. Shah N, Williams A. Surviving the asbestos epidemic. Insur Digest (Eur). 2001;15:14–18
  3. Leigh J: Asbestos-related diseases: International estimates of future liability. Proc Int Cong Work Injuries Prev, Rehab, Compensation (Workcongress5); Adelaide, 2001, p. 102
  4. Wagner JC, Sleggs CA, Marchand P. Diffuse pleural mesothelioma and asbestos exposure in the North Western Cape Province. Br J Ind Med. 1960;17:260–271
  5. Roggli VL, Sharma A, Butnor KJ, et al. MM and occupational exposure to asbestos: A clinicopathological correlation of 1445 cases. Ultrastruct Pathol. 2002;26:55–65
  6. Schottenfeld D, Fraumeni JF. Cancer Epidemiology and Prevention. Philadelphia, PA: WB Saunders; 1982;
  7. U.S. Department of Labor OSaHA. Safety and Health Topics: Asbestos. 2003;[Internet Communication]
  8. Selikoff IJ, Hammond EC, Seidman H. Latency of asbestos disease among insulation workers in the United States and Canada. Cancer. 1980;46:2736–2740
  9. National Academy of Sciences. Asbestiform Fibers: Non-Occupational Health Risks. Washington, DC: National Academies Press; 1984;
  10. Mossman BT, Bignon J, Corn M, et al. Scientific developments and implications for public policy. Science. 1990;247:294–301
  11. Lange JH. Cough and bronchial responsiveness in firefighters at the World Trade Center site. N Engl J Med. 2003;348:76–77
  12. Lioy PJ, Weisel CP, Millette JR, et al. Characterization of the dust/smoke aerosol that settled east of the World Trade Center (WTC) in lower Manhattan after the collapse of the WTC 11 September 2001. Environ Health Perspect. 2002;110:703–714
  13. Wallingford KM, Snyder EM. Occupational exposures during the World Trade Center disaster response. Toxicol Ind Health. 2001;17(5-10):247–253
  14. Dodson RF, Williams MG, Satterley JD. Asbestos burden in two cases of mesothelioma where the work history included manufacturing of cigarette filters. J Toxicol Environ Health A. 2002;65:1109–1120
  15. Harries PG, Mackenzie FA, Sheers G, et al. Radiological survey of men exposed to asbestos in naval dockyards. Br J Ind Med. 1972;29:274–279
  16. Koskinen K, Rinne JP, Zitting A, et al. Screening for asbestos-induced diseases in Finland. Am J Ind Med. 1996;30:241–251
  17. Karjalainen A, Pukkala E, Kauppinen T, et al. Incidence of cancer among Finnish patients with asbestos-related pulmonary or pleural fibrosis. Cancer Causes Control. 1999;10:51–57
  18. Barnhart S, Keogh J, Cullen MR, et al. The CARET asbestos-exposed cohort: Baseline characteristics and comparison to other asbestos-exposed cohorts. Am J Ind Med. 1997;32:573–581
  19. Omenn GS, Goodman G, Thornquist M, et al. The beta-carotene and retinol efficacy trial (CARET) for chemoprevention of lung cancer in high risk populations: Smokers and asbestos-exposed workers. Cancer Res. 1994;54(suppl):2038s–2043s
  20. Henschke CI, McCauley DI, Yankelevitz DF, et al. Early lung cancer action project: Overall design and findings from baseline screening. Lancet. 1999;354:99–105
  21. Tiitola M, Kivisaari L, Huuskonen MS, et al. Computed tomography screening for lung cancer in asbestos-exposed workers. Lung Cancer. 2002;35:17–22
  22. Vierikko T, Jarvenpaa R, Autti T, et al. Chest CT screening of asbestos-exposed workers: Lung lesions and incidental findings. Eur Respir J. 2007;29:78–84
  23. Fasola G, Belvedere O, Aita M, et al. Low-dose computed tomography screening for lung cancer and pleural mesothelioma in an asbestos-exposed population: Baseline results of a prospective, nonrandomized feasibility trial—An Alpe-adria Thoracic Oncology Multidisciplinary Group Study (ATOM 002). Oncologist. 2007;12:1215–1224
  24. Das M, Muhlenbruch G, Mahnken AH, et al. Asbestos Surveillance Program Aachen (ASPA): Initial results from baseline screening for lung cancer in asbestos-exposed high-risk individuals using low-dose multidetector-row CT. Eur Radiol. 2007;17:1193–1199
  25. Roberts HC, Patsios DA, Paul NS, et al. Screening for malignant pleural mesothelioma and lung cancer in individuals with a history of asbestos exposure. J Thorac Oncol. 2009;(in press)
  26. Egedahl RD, Olsen GW, Coppock E, et al. An historical prospective mortality study of the Sarnia Division of Dow Chemical Canada Inc., Sarnia, Ontario (1950-1984). Can J Pub Health. 1989;80(6):441–446
  27. Robinson M, Wiggins J. Statement on MM in the UK. Thorax. 2002;57:187
  28. Scherpereel A. Guidelines of the French Speaking Society for chest medicine for management of malignant pleural mesothelioma. Respir Med. 2006;101(6):1265–1276
  29. Ebert W, Hoppe M, Muley T, et al. Monitoring of therapy in inoperable lung cancer patients by measurement of CYFRA 21-1, TPA-TP Cea, and NSE. Anticancer Res. 1997;17:2875–2878
  30. Pettersson T, Fröseth B, Riska H, et al. Concentration of hyaluronic acid in pleural fluid as a diagnostic aid for MM. Chest. 1988;94:1037–1039
  31. Frebourg T, Lerebours G, Delpech B, et al. Serum hyaluronate in malignant pleural mesothelioma. Cancer. 1987;59:2104–2107
  32. Roboz J, Greaves J, Silides D, et al. Hyaluronic acid content of effusions as a diagnostic aid for MM. Cancer Res. 1985;45:1850–1854
  33. Chiu B, Churg A, Tengblad A, et al. Analysis of hyaluronic acid in the diagnosis of MM. Cancer. 1984;54:2195–2199
  34. Boersma A, Degand P, Biserte G. Hyaluronic acid analysis and the diagnosis of pleural mesothelioma. Bull Physiol Pathol Respir (Nancy). 1980;16:41–45
  35. Hellstrom PE, Friman C, Teppo L. Of 17 years' duration with high pleural fluid concentration of hyaluronate. Scand J Respir Dis. 1977;58:97–102
  36. Thylen A, Wallin J, Martensson G. Hyaluronan in serum as an indicator of progressive disease in hyaluronan-producing MM. Cancer. 1999;86:2000–2005
  37. Pluygers E, Baldewyns P, Minette P, et al. Biomarker assessments in asbestos-exposed workers as indicators for selective prevention of mesothelioma or bronchogenic carcinoma: Rationale and practical implementations. Eur J Cancer Prev. 1992;1(2):129–138
  38. Hedman M, Arnberg H, Wernlund J, et al. Tissue polypeptide antigen (TPA), hyaluronan and ca 125 as serum markers in MM. Anticancer Res. 2003;23:531–536
  39. Paganuzzi M, Onetto M, Marroni P, et al. Diagnostic value of CYFRA 21-1 tumor marker and CEA in pleural effusion due to mesothelioma. Chest. 2001;119:1138–1142
  40. Lee YC, Knox BS, Garrett JE. Use of cytokeratin fragments 19.1 and 19.21 (Cyfra 21-1) in the differentiation of malignant and benign pleural effusions. Aust NZ J Med. 1999;29:765–769
  41. Schouwink H, Korse CM, Bonfrer JM, et al. Prognostic value of the serum tumour markers Cyfra 21-1 and tissue polypeptide antigen in MM. Lung Cancer. 1999;25:25–32
  42. Marukawa M, Hiyama J, Shiota Y, et al. The usefulness of CYFRA 21-1 in diagnosing and monitoring malignant pleural mesothelioma. Acta Med Okayama. 1998;52:119–123
  43. Cremades MJ, Menendez R, Pastor A, et al. Diagnostic value of cytokeratin fragment 19 (CYFRA 21-1) in bronchoalveolar lavage fluid in lung cancer. Respir Med. 1998;92:766–771
  44. Bonfrer JM, Schouwink JH, Korse CM, et al. 21-1 And TPA as markers in MM. Anticancer Res. 1997;17:2971–2973
  45. Almudevar BE, Garcia-Rostan Perez GM, Garcia BF, et al. Prognostic value of high serum levels of ca-125 in malignant secretory peritoneal mesotheliomas affecting young women (A case report with differential diagnosis and review of the literature). Histopathology. 1997;31:267–273
  46. Chang K, Pai LH, Pass H, et al. Monoclonal antibody K1 reacts with epithelial mesothelioma but not with lung adenocarcinoma. Am J Surg Pathol. 1992;16:259–268
  47. Brinkmann U, Webber K, Di Carlo A, et al. Cloning and expression of the recombinant FAb fragment of monoclonal antibody K1 that reacts with mesothelin present on mesotheliomas and ovarian cancers. Int J Cancer. 1997;71:638–644
  48. Ordonez NG. Value of mesothelin immunostaining in the diagnosis of mesothelioma. Mod Pathol. 2003;16:192–197
  49. Ordonez NG. Application of mesothelin immunostaining in tumor diagnosis. Am J Surg Pathol. 2003;27:1418–1428
  50. Hassan R, Remaley AT, Sampson ML, et al. Detection and quantitation of serum mesothelin, a tumor marker for patients with mesothelioma and ovarian cancer. Clin Cancer Res. 2006;12:447–453
  51. Wali A, Morin PJ, Hough CD, et al. Identification of intelectin overexpression in malignant pleural mesothelioma by serial analysis of gene expression (SAGE). Lung Cancer. 2005;48:19–29
  52. Onda M, Nagata S, Ho M, et al. Megakaryocyte potentiation factor cleaved from mesothelin precursor is a useful tumor marker in the serum of patients with mesothelioma. Clin Cancer Res. 2006;12:4225–4231
  53. Scherpereel A, Grigoriu B, Conti M, et al. Soluble mesothelin-related peptides in the diagnosis of malignant pleural mesothelioma. Am J Respir Crit Care Med. 2006;173:1155–1160
  54. Scholler N, Fu N, Yang Y, et al. Soluble member(s) of the mesothelin/megakaryocyte potentiating factor family are detectable in sera from patients with ovarian carcinoma. Proc Natl Acad Sci USA. 1999;96:11531–11536
  55. Robinson BW, Creaney J, Lake R, et al. Mesothelin-family proteins and diagnosis of mesothelioma. Lancet. 2003;362:1612–1616
  56. Creaney J, Yeoman D, Demelker Y, et al. Comparison of osteopontin, megakaryocyte potentiating factor, and mesothelin proteins as markers in the serum of patients with MM. J Thorac Oncol. 2008;3:851–857
  57. Park EK, Sandrini A, Yates DH, et al. Soluble mesothelin-related protein in an asbestos-exposed population: The dust diseases board cohort study. Am J Respir Crit Care Med. 2008;178:832–837
  58. Creaney J, van Bruggen I, Hof M, et al. Combined CA125 and mesothelin levels for the diagnosis of MM. Chest. 2007;132:1239–1246
  59. Robinson BW, Creaney J, Lake R, et al. Soluble mesothelin-related protein—A blood test for mesothelioma. Lung Cancer. 2005;49(suppl 1):S109–S111
  60. Portal JR, Becerra ER, Rodriguez DR, et al. Serum levels of soluble mesothelin-related peptides in malignant and nonmalignant asbestos-related pleural disease: Relation with past asbestos exposure. Cancer Epidemiol Biomarkers Prev. 2009;18:646–650
  61. Pass HI, Wali A, Tang N, et al. Soluble mesothelin-related peptide level elevation in mesothelioma serum and pleural effusions. Ann Thorac Surg. 2008;85:265–272
  62. Creaney J, Yeoman D, Naumoff L, et al. Soluble mesothelin in effusions—A useful tool for the diagnosis of MM. Thorax. 2007;62(7):569–576
  63. Grigoriu BD, Chahine B, Scherpereel A. Kinetics of soluble mesothelin in patients with malignant pleural mesothelioma during treatment. Am J Respir Crit Care Med. 2009;179(10):950–954
  64. Ivanov SV, Ivanova AV, Goparaju CM, et al. Tumorigenic properties of alternative osteopontin isoforms in mesothelioma. Biochem Biophys Res Commun. 2009;382:514–518
  65. Sandhu H, Dehnen W, Roller M, et al. mRNA expression patterns in different stages of asbestos-induced carcinogenesis in rats. Carcinogenesis. 2000;21:1023–1029
  66. Pass HI, Lott D, Lonardo F, et al. Asbestos exposure, pleural mesothelioma, and serum osteopontin levels. N Engl J Med. 2005;353:1564–1573
  67. Park EK, Thomas PS, Johnson AR, et al. Levels in an asbestos-exposed population. Clin Cancer Res. 2009;15:1362–1366
  68. Grigoriu BD, Scherpereel A, Devos P, et al. Utility of osteopontin and serum mesothelin in malignant pleural mesothelioma diagnosis and prognosis assessment. Clin Cancer Res. 2007;13:2928–2935
  69. Beck A, Ivanova A, Pass HI. Evaluation of plasma osteopontin as early detection and prognostic marker in malignant pleural mesothelioma. J Clin Oncol. 2008;26:A11074;(abstract)
  70. Carbone M, Emri S, Dogan AU, et al. A mesothelioma epidemic in Cappadocia: Scientific developments and unexpected social outcomes. Nat Rev Cancer. 2007;7:147–154

 Dr. Pass has a patent application for the use of osteopontin in asbestos-related malignancies.

PII: S1043-0679(09)00071-9

doi: 10.1053/j.semtcvs.2009.06.007

Seminars in Thoracic and Cardiovascular Surgery
Volume 21, Issue 2 , Pages 97-104 , Summer 2009

Article Tools